CN Patent

CN114369130B — 修饰的硫代寡核苷酸及其应用

Assigned to Hangzhou Tianlong Pharmaceutical Co Ltd · Expires 2023-10-03 · 3y expired

What this patent protects

本发明提供一种修饰的硫代寡核苷酸及其应用。所述修饰的硫代寡核苷酸为硫代寡核苷酸YK102的5′末端的最后2～5个核苷酸和3′末端的最后2～5个核苷酸经过gapmer修饰而成的寡核苷酸。本发明采用gapmer策略对硫代寡核苷酸YK102的序列侧翼进行行化学修饰，从而大大提高了硫代寡核苷酸的稳定性和生物学活性，降低了细胞毒性，可用于治疗肿瘤。

USPTO Abstract

本发明提供一种修饰的硫代寡核苷酸及其应用。所述修饰的硫代寡核苷酸为硫代寡核苷酸YK102的5′末端的最后2～5个核苷酸和3′末端的最后2～5个核苷酸经过gapmer修饰而成的寡核苷酸。本发明采用gapmer策略对硫代寡核苷酸YK102的序列侧翼进行行化学修饰，从而大大提高了硫代寡核苷酸的稳定性和生物学活性，降低了细胞毒性，可用于治疗肿瘤。

Drugs covered by this patent

Patent Metadata

Patent number
CN114369130B
Jurisdiction
CN
Classification
—
Expires
2023-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Hangzhou Tianlong Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.